Medhealth Outlook - Altasciences: 30 Years of Innovation in Translational Science and Clinical Success
Altasciences At CPHI Americas 2025 | By Lisa Sanford
In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster.
Altasciences at ARVO 2025: An Eye on the Future of Ophthalmic Drug Development by Gretchen Green
Altasciences recently attended and exhibited at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held at the Salt Palace Convention Center against the stunning backdrop of downtown Salt Lake City, Utah—arguably one of the most scenic U.S. conference locations.
CNS Drug Development Solutions, Simplified.
The Golden Era of GLP-1 Drugs: How Will it Impact Medicine and Society? by Dr. Gaetano Morelli MD, Chief Medical Officer and Executive Vice President Medical Affairs
Case Study: Two Examples of Successful Automation Integration at Altasciences for Pharmacokinetic Studies
By Martin Rougée, Optimization Scientist, Bioanalytical Operations
Automation offers several advantages to any industry. For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. For biotechnology and pharmaceutical companies, automation can decrease their drug-to-market development time and remain financially competitive in an evolving market.